2018
DOI: 10.1016/j.ijcard.2018.04.136
|View full text |Cite
|
Sign up to set email alerts
|

Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction

Abstract: Tocilizumab led to a selective and substantial increase in IP-10 and MIP-1β during the acute phase of NSTEMI, with no or only minor effects on the other measured cytokines. ClinicalTrials.gov, NCT01491074.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
14
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(15 citation statements)
references
References 25 publications
0
14
0
1
Order By: Relevance
“…In non-ST elevation myocardial infarction (non-STEMI) patients, a single dose of tocilizumab administered prior to coronary angiography was safe and attenuated troponin T release and systemic inflammation [110]. Although IL-6 blockade reduced serum CRP, levels of the chemokines CXCL10 and CCL4 were increased, highlighting the complexity of IL-6 actions on inflammatory cascades [111].…”
Section: Targeting Il-6 In Human Heart Failurementioning
confidence: 99%
“…In non-ST elevation myocardial infarction (non-STEMI) patients, a single dose of tocilizumab administered prior to coronary angiography was safe and attenuated troponin T release and systemic inflammation [110]. Although IL-6 blockade reduced serum CRP, levels of the chemokines CXCL10 and CCL4 were increased, highlighting the complexity of IL-6 actions on inflammatory cascades [111].…”
Section: Targeting Il-6 In Human Heart Failurementioning
confidence: 99%
“…It is given by injection intravenously and/or subcutaneously [104] and has undergone limited evaluation for efficacy in CVD. A recently completed phase II clinical trial examined its ability to reduce acute vascular inflammation in nonS/T-elevation myocardial infarction (NSTEMI) patients; however, the anticipated cardioprotective effect was not clear-cut, with tocilizumab causing a selective upregulation of inflammatory mediators interferon gamma-inducible protein 10 (IP-10) and macrophage inflammatory protein-1 β (MIP-1 β ) [105]. Given that many patients undergoing CVD interventions already suffer from underlying chronic inflammation observed in conditions such as T2DM, this potential proinflammatory effect may limit its usefulness in the clinic.…”
Section: Opportunities For Therapeutic Applicationsmentioning
confidence: 99%
“…Given that many patients undergoing CVD interventions already suffer from underlying chronic inflammation observed in conditions such as T2DM, this potential proinflammatory effect may limit its usefulness in the clinic. Furthermore, this clinical trial was not able to fully recapitulate the effects of tocilizumab that were evident in vitro [105].…”
Section: Opportunities For Therapeutic Applicationsmentioning
confidence: 99%
“…As previously described, the use of IL6-RA in NSTEMI patients, at a dosage considerably lesser than in the present trial, reduced hsCRP and troponin levels [ 21 ], as well as altered cytokine levels [ 30 ]. The degree of systemic inflammation in these NSTEMI patients was much lesser than observed after OHCA and likely the effects of IL-6RA will be of a different magnitude in the present trial; likewise, a substantial proportion of OHCA patients in this trial will present with STEMI, again leading to higher levels of myocardial injury and troponin release.…”
Section: Discussionmentioning
confidence: 78%